Analysts don't expect Nio to reach profitability for years. Should you buy the Chinese automaker's stock anyway?Shares of Chinese electric vehicle (EV) manufacturer Nio (NIO 5.01%) were on the rise for a second straight day on Friday, adding 5.6% through 1 p.m. ET on top of Thursday's 6% gain.You can probably thank Morgan Stanley for that. What Morgan Stanley says about NioIn a note that came out Thursday afternoon, Morgan Stanley analyst Tim Hsiao reiterated his overweight rating on Nio and praised its new ...

This exclusive Las Vegas experience will include a draft party moderated by former All-Pro quarterback Matt Ryan with insider insights and pick reactionsLAS VEGAS, July 9, 2025 /PRNewswire/ -- BetMGM, a leading sports betting and iGaming operator, and Marriott Bonvoy unveiled a first-of-its-kind rewards collaboration in 2024. Together, they are now launching the ultimate fantasy football draft weekend.One lucky fan will win a once-in-a-lifetime Las Vegas draft party hosted by former All-Pro quarterback Matt ...

BETHESDA, Md., July 8, 2025 /PRNewswire/ -- Marriott International, Inc. (Nasdaq: MAR) will report second quarter 2025 earnings results on Tuesday, August 5, 2025, at approximately 7:00 a.m. Eastern Time (ET). The company will hold a conference call for the investment community on Tuesday, August 5, 2025, at 8:30 a.m. (ET). Marriott International's President and Chief Executive Officer, Anthony Capuano, and Chief Financial Officer and Executive Vice President, Development, Leeny Oberg, will discuss the comp ...

Core Viewpoint - NIO Inc. is currently undervalued with a forward price/sales ratio of 0.46X, significantly lower than its five-year average of 1.63X, and faces operational inefficiencies and high leverage that raise concerns about its future prospects [1][5][14]. Financial Performance - NIO's shares have underperformed over the past year, declining by 21.3%, while competitors XPeng and Li Auto have seen gains of 153% and 28.5%, respectively [3]. - The company's long-term debt to capital ratio is 0.76, which is substantially higher than the industry average of 0.28, indicating elevated leverage that limits financial flexibility [9]. Operational Challenges - NIO has expanded its vehicle lineup with the ONVO brand, but sales performance has not met expectations, leading to challenges in managing the product and vehicle margins [7]. - SG&A expenses increased by 46.8% year-over-year, contributing to operational inefficiencies and high operating costs that are expected to continue [8]. Growth Prospects - NIO forecasts Q2 deliveries of 72,000 to 75,000 vehicles, representing a year-over-year growth of 25.5% to 30.7%, supported by an expanding vehicle portfolio and strategic initiatives [11]. - Vehicle margins improved to 10.2% in Q1 2025 from 9.2% in Q1 2024, driven by lower material costs per unit, indicating a positive trend [11]. Product Launches - The launch of the NIO ET9, which surpassed competitors in sales during its initial months, along with new models like ES6 and EC6, is expected to enhance overall vehicle margins [10][12]. - The company aims to achieve breakeven by Q4 2025, which is viewed as a positive indicator for future performance [13][15].

Core Viewpoint - Intellia Therapeutics (NTLA) has demonstrated significant stock performance, with a 29.8% increase over the past month, outperforming the industry and the S&P 500 index [1][7]. Company Performance - The company's stock performance is attributed to advancements in its pipeline development and increased interest in gene therapies following Eli Lilly's acquisition of Verve Therapeutics [3][4]. - Intellia is transitioning towards becoming a commercial-ready organization by the end of 2026 [9]. Pipeline Development - Intellia is advancing two late-stage in vivo candidates: nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) [4][8]. - Nex-z is currently undergoing two phase III studies, with enrollment in the MAGNITUDE 2 study expected to complete by 2026 and a potential biologics license application planned for 2028 [5][6]. - Lonvo-z is in the pivotal phase III HAELO study, with enrollment expected to complete by Q3 2025 and a regulatory filing planned for the second half of 2026 [8]. Competitive Landscape - Intellia faces competition from other companies utilizing CRISPR/Cas9 technology, such as CRISPR Therapeutics, which recently received approval for its gene-edited therapy, Casgevy [12][13]. - The company has decided to halt the development of its in vivo gene insertion candidate, NTLA-3001, and plans to reduce its workforce by nearly 27% in 2025 [13]. Financial Outlook - NTLA shares currently trade at a price/book ratio of 1.43, below the industry average of 3.13 [14]. - The Zacks Consensus Estimate for NTLA's loss per share has narrowed for both 2025 and 2026, indicating a potential improvement in financial performance [16]. Conclusion - Intellia's recent stock rally is promising, but the lack of an approved product remains a significant challenge [17]. - The successful development of its pipeline candidates is crucial for the company's future [17][18].

Marking Marriott's first luxury hotel and residential offerings in Calgary, W Calgary & JW Marriott Calgary, along with an Autograph Collection Hotel, are set to deliver a new standard of hospitality in the heart of the cityCALGARY, AB, July 2, 2025 /PRNewswire/ -- Truman and Marriott International, Inc. announced today plans to open three hotels in Calgary, including W Calgary, JW Marriott Calgary and an Autograph Collection Hotel on Stampede Park. These brands are poised to transform the hospitality lands ...

Core Insights - NIO Inc. reported a total of 24,925 vehicle deliveries in June, marking a year-over-year growth of 17.5%. For Q2, the company delivered 72,056 vehicles, which is a 25.6% increase compared to the same quarter last year and within the company's guidance range [1][9]. Delivery Performance - In Q2, NIO's namesake brand sold 47,132 cars, reflecting an approximate decline of 18% from the same quarter in 2024. The ONVO brand delivered 17,081 units, while Firefly delivered 7,843 units [2]. - The ONVO and Firefly brands have diversified NIO's product portfolio, contributing to sales momentum, but this growth appears to be at the expense of the core NIO brand [3]. Year-to-Date Performance - In the first half of 2025, NIO sold 114,150 vehicles, representing an increase of over 30% from the previous year. However, this growth is insufficient to meet the company's ambitious target of doubling sales to 330,000 vehicles in 2025 [4][5]. Competitive Landscape - Li Auto delivered 36,279 units in June and 111,074 vehicles in Q2 2025, with a modest growth rate of 2.3%. XPeng Inc. delivered 34,611 smart EVs in June, achieving a remarkable 224% year-over-year increase and setting a new quarterly record with 103,181 cars sold in Q2 [6][7]. Stock Performance - NIO's shares have declined approximately 19% year-to-date, compared to an 8% decline in the broader industry [8]. Valuation Metrics - NIO currently trades at a forward price-to-sales ratio of 0.45 and holds a Value Score of D, indicating potential concerns regarding its valuation [10].

Key Takeaways CRSP is the first to market a CRISPR/Cas9 therapy, with Casgevy approved for SCD and TDT in multiple regions CRSP's pipeline spans ex vivo and in vivo therapies, including early success with CTX310. NTLA focuses on late-stage in vivo programs but faces setbacks, including a liver safety concern with nex-z.CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the f ...

Group 1: Market Overview - The market presents compelling opportunities for investors seeking attractively priced stocks, with some quality picks available under $10 [1] - OpenAI's ChatGPT has identified two notable stocks trading below $10 that warrant further investigation [1] Group 2: AMC Entertainment - AMC Entertainment is priced at approximately $3.15 per share, reflecting a year-to-date decline of over 21% [2] - The theater chain achieved its third-highest five-day revenue total in over a decade, with over seven million moviegoers attending its cinemas during Memorial Day weekend [4] - The holiday period also recorded the best Friday-through-Sunday attendance of 2025, with food and beverage sales reaching their highest five-day total in the 2020s, second only to one other period in the company's history [5] - AMC's strong brand recognition and high short interest position it as a potential candidate for a short squeeze, which could yield significant returns for speculative investors [5] Group 3: Nio - Nio's shares are currently priced at $3.51, down over 3% for the day and 22% year-to-date, presenting a potential long-term buying opportunity [6] - Known as "China's Tesla," Nio remains a key player in the electric vehicle (EV) market, supported by the Chinese government and aligned with national policies promoting EV growth [8] - Nio has initiated deliveries of its second brand, Onvo, in late 2024, and plans to launch a third brand, Firefly, in 2025, targeting 440,000 vehicle deliveries this year, which could enhance revenue and margin expansion [9] - Signs indicate that the intense EV price war in China may be easing, making Nio an attractive long-term investment for those willing to endure short-term volatility [9]

Core Insights - Intellia Therapeutics announced promising three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study for lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) [1][2] - All 10 patients in the Phase 1 study were attack-free and treatment-free for a median of nearly two years, demonstrating the potential of lonvo-z as a one-time therapy [2][6] - The global Phase 3 HAELO trial has completed screening ahead of schedule, with over half of the patients screened in the United States [4][6] Clinical Results - A single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% compared to pre-treatment baseline [2][6] - Patients showed deep, dose-dependent, and durable reductions in plasma kallikrein protein levels throughout the study [2][6] - The treatment was well tolerated, with the most frequent adverse events being infusion-related reactions, which were mostly Grade 1 and resolved without complications [3][6] Development Plans - The ongoing Phase 3 HAELO trial is randomized, double-blind, and placebo-controlled, assessing the safety and efficacy of lonvo-z at the 50 mg dosage [4][5] - Intellia plans to submit a biologics license application (BLA) in 2026, aiming for a U.S. launch in 2027 [4][8] - New data from the Phase 2 portion of the ongoing Phase 1/2 study is expected to be presented in the second half of 2025 [4][10] About Lonvo-z - Lonvo-z is based on CRISPR/Cas9 technology and aims to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene [8] - The therapy has received multiple regulatory designations, including Orphan Drug and RMAT Designation from the FDA [8][9] - Intellia is focused on leveraging gene editing technology to develop novel therapies that address unmet medical needs [9]